by Sean Hughes | May 1, 2020 | Briefings, EPO
Background In T 1063/18 (Peppers), the Board held that Rule 28(2) EPC should be disregarded, and that plants produced by essentially biological processes should be considered patentable. Specifically, the Board found that the EPO Administrative Council’s...
by Alex Bajjon | Apr 1, 2020 | Briefings, US & International
Genentech owns US Patents 7,846,441 and 7,892,549 which both relate to treating cancers characterised by overexpression of the ErbB2 receptor (which includes breast cancers). The claims of these two patents relate to treating a human patient with a combination of an...
by Alex Bajjon | Apr 1, 2020 | Briefings, EPO, UK
The information in this article is believed to be correct at the time of writing (1 May 2020). Please visit the EPO, UKIPO and EUIPO websites that are being continually updated for the most up-to-date information: EPO: https://www.epo.org/news-issues/covid-19.html...
by David Eyre | Mar 1, 2020 | Briefings, UK
“Crown Use”, by which the government can order the infringement of the patent under particular circumstances, is a provision of the UK Patents Act 1977 that is seldom used. However, in the case of IPCom vs Vodafone, this seldom used provision has been...
by Carolyn Haywood | Mar 1, 2020 | Briefings, US & International
Earlier this month, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued its judgement in Illumina, Inc. v. Ariosa Diagnostics, Inc. and if the judgement stands, it may offer diagnostic companies a new way of navigating 35 U.S.C. § 101 – by way of...
Recent Comments